Siebert v. Gene Security Network, Inc.

75 F. Supp. 3d 1108, 96 Fed. R. Serv. 76, 2014 U.S. Dist. LEXIS 166417, 2014 WL 6765835
CourtDistrict Court, N.D. California
DecidedDecember 1, 2014
DocketCase No. 11-cv-01987-JST
StatusPublished
Cited by13 cases

This text of 75 F. Supp. 3d 1108 (Siebert v. Gene Security Network, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Siebert v. Gene Security Network, Inc., 75 F. Supp. 3d 1108, 96 Fed. R. Serv. 76, 2014 U.S. Dist. LEXIS 166417, 2014 WL 6765835 (N.D. Cal. 2014).

Opinion

[1111]*1111ORDER GRANTING IN PART AND DENYING IN PART MOTION FOR SUMMARY JUDGMENT AND DENYING MOTION FOR PARTIAL SUMMARY JUDGMENT

Re: ECF Nos. 109, 110

JON S. TIGAR, United States District Judge

Before the Court are Plaintiff Gary Siebert’s Motion for Summary Judgment or, in the alternative, for summary adjudication, and Defendant Gene Security Network’s Motion for Partial Summary Judgment. ECF Nos. 109, 110. For the reasons set forth below, Siebert’s Motion for Summary Judgment is GRANTED IN PART and DENIED IN PART, and Defendant’s Motion for Partial Summary Judgment is DENIED.

I. BACKGROUND

On April 22, 2011, Plaintiff-relator Gary Siebert filed this False Claims Act (“FCA”) case, alleging that Defendant Gene Security Network (“GSN”)1 falsely certified its compliance with accounting regulations and thereby unlawfully secured at least three grants from the National Institutes of Health (“NIH”). ECF No. 1. Specifically, Siebert alleges that GSN “knowingly submitted a false or fraudulent claim for payment or approval, and knowingly presented false records or state-, ments to get a false or fraudulent claim paid or approved, in violation of 31 U.S.C. § 3729(a)(1) and (2).” ECF No. 22, ¶6. Siebert served as GSN’s Chief Operating Officer and Vice President of Research from July 12, 2010 until GSN terminated his employment on February 11, 2011. Id. ¶ 12.

GSN is a private biotechnology company that studies and conducts minimally invasive embryonic tests for the presence of genetic disorders. ECF No. 110 at 2. Matthew Rabinowitz, the company’s CEO, founded the company in 2003. Id. at 1. Rabinowitz has testified that he managed financial matters and accounting for GSN from “the very early days,” but that later on, the company hired “other people to manage that-” ECF No. 110 at 2-3. Rabinowitz also participated in research and helped prepare and submit the grant proposals at issue here. ECF No. 110-3 at 6-7,10.

Three NIH grants totaling $5,293,373 form the basis of Siebert’s claims: $1,689,902 from the “Novel Informatics” grant, $1,799,814 from the “Array Informatics” grant, and $1,803,657 from the “Non-Invasive Aneuploidy” grant. ECF No. 109 at 1-2. GSN applied for the grants on December 12, 2007, April 7, 2008, and August 5, 2009, respectively. Id. at 2. GSN drew funds from those grants on nine separate occasions. ECF No. 109-40, Exs. 1-9.2

[1112]*1112GSN hired various employees as it expanded over the years. The employees most pertinent to this motion — in addition to Rabinowitz — are John Croswell, whom GSN hired before applying for any of the NIH grants, Robin McElroy, whom GSN hired in 2007, and Venkata Peddada-West, who replaced McElroy after McElroy suffered a stroke in 2010. John Croswell held general management responsibilities, including those related to accounting, the “handling of grant funds,” and interacting with the NIH grant office. ECF No. 110 at 3. McElroy was hired to handle administrative tasks, her responsibilities including “accounting manager, HR manager, facilities manager and office manager.” Id. at 3-4. She input accounting data into Quiekbooks and maintained accounting records for the company. Id. at 4. When McElroy became ill, various employees took over her responsibilities until West was hired and became accountant and office manager. Id.

At the time GSN applied for the three NIH grants, no GSN employee had experience with NIH grants. ECF No. 110 at 4-5. Rabinowitz, Croswell, McElroy, White, and several other employees have testified that they were not familiar with the specifics of the accounting regulations contained in 45 C.F.R. Part 74, and Rabi-nowitz has testified that he believed the only requirement in these regulations was the requirement that grant funds be used for the research NIH intended the grant to fund. Id. at 5-6.

Nonetheless, as part of the application process, GSN employees signed certifications that they were in compliance with the requirements of 45 C.F.R. Part 74.3 The certifications were located in the “NIH Small Business Innovation Research Program Small Business Concern Verification Statement,” and read:

It is understood that if this project is funded, drawing NIH award funds from the HHS Payment Management System serves as a certification that the above-named organization has in place written policies and procedures for financial and business management systems that comply with 45 CFR 74 and the NIH Grants Policy Statement (12/03) and will follow these policies and procedures.

ECF No. 109-Í5. This statement indicates that each drawdown of grant funds constitutes a discrete certification of compliance with 45 C.F.R. Part 74.

In August 2008, McElroy filled out a questionnaire from NIH. ECF No. 118 at 3^4; see ECF No. 109, Ex. D. That questionnaire was titled “Financial Questionnaire: Evaluation of Financial Management Systems,” and contained the following pertinent language:

Financial management system requirements for grantee organizations of the National Institutes of Health (NIH) are addressed in the NIH Grants Policy Statement (NIHGPS) and Title 45 Code of Federal Regulations (CFR) Part 74.21. Grantee organizations are expected to have certain systems, policies, and procedures in place for managing [1113]*1113their own funds, equipment, and personnel.

ECF No. 118 at 4 (citations omitted).

Like the certifications and questionnaire, the NIH Grants Policy Statement (“Statement”) required compliance with 45 C.F.R. Part 74. ECF No. 109 at 4. Section 8.3.1 of the Statement provides:

Grantees are required to meet the standards and requirements for financial management systems, set forth or referenced in 45 CFR part 74.21 or 92.20, as applicable. The standards and requirements for a financial management system are essential to the grant relationship. NIH cannot support the research unless it has assurance that its funds will be used appropriately, adequate documentation of transactions will be maintained, and assets will be safeguarded.
Grantees must have in place accounting and internal control systems that provide for appropriate monitoring of grant accounts to ensure that obligations and expenditures are reasonable, allocable, and allowable....
A grantee’s failure to establish adequate control systems constitutes a material violation of the terms of the award. Under these circumstances, NIH .may include special conditions on awards or take any of the range of actions specified in Administrative Requirements-Enforcement Actions, as necessary and appropriate.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Morsell v. Symantec Corporation
District of Columbia, 2023
United States ex rel. Durkin v. Cnty. of San Diego
300 F. Supp. 3d 1107 (S.D. California, 2018)
Aparicio v. Comcast, Inc.
274 F. Supp. 3d 1014 (N.D. California, 2017)
Graves v. Plaza Medical Centers, Corp.
276 F. Supp. 3d 1335 (S.D. Florida, 2017)
Prime Healthcare Services, Inc. v. Harris
216 F. Supp. 3d 1096 (S.D. California, 2016)
Cleveland v. Groceryworks.com, LLC
200 F. Supp. 3d 924 (N.D. California, 2016)
Langenbau v. Med-Trans Corp.
167 F. Supp. 3d 983 (N.D. Iowa, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
75 F. Supp. 3d 1108, 96 Fed. R. Serv. 76, 2014 U.S. Dist. LEXIS 166417, 2014 WL 6765835, Counsel Stack Legal Research, https://law.counselstack.com/opinion/siebert-v-gene-security-network-inc-cand-2014.